

CURRICULUM VITAE - Carolyn J. Anderson, Ph.D.

DATE: February 18, 2009

PERSONAL:

Sex: Female
Date of Birth: November 12, 1962
Place of Birth: Superior, Wisconsin
Citizenship: USA

ADDRESS:

Office:

Washington University Medical School
Division of Radiological Sciences
510 S. Kingshighway Blvd. Campus Box 8225
St. Louis, MO 63110
Telephone: (314)362-8427
Fax: (314)362-9940
e-mail: andersoncj@wustl.edu

Home:

7145 Waterman Ave
St. Louis, MO 63130
Telephone: (314) 727-8846

PRESENT POSITION:

Professor: School of Medicine; Department of Radiology
Professor: School of Arts and Sciences; Department of Chemistry
Professor: School of Medicine, Department of Biochemistry

EDUCATION:

Undergraduate: University of Wisconsin Superior, Superior, WI-B.S.-1985-Chemistry
Graduate: Florida State University, Tallahassee, FL-Ph.D.-1990-Inorganic Chemistry

ACADEMIC POSITIONS/EMPLOYMENT:

1985-1986 Teaching Assistant, Chemistry, Florida State University, Tallahassee, FL
1986-1990 Research Assistant, Chemistry, Florida State University, Tallahassee, FL
1990-1992 Research Associate, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO
1993-1999 Assistant Professor, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO
1996-2001 Assistant Professor, Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, MO

- 2000-2006 Associate Professor, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO
- 2000-2008 Associate Professor, Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, MO
- 2006- Co-Director, Graduate Pathway in Imaging Sciences, Division of Biology and Biomedical Sciences, Washington University
- 2007- Professor, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO
- 2007- Professor, Department of Chemistry, School of Arts and Sciences, Washington University
- 2008- Professor, Department of Biochemistry, Washington University School of Medicine, St. Louis, MO

UNIVERSITY APPOINTMENTS AND COMMITTEES

- 1993-1994 Imaging Center Dedication Committee, Mallinckrodt Institute of Radiology
- 1993-1998 Animal Studies Committee, Washington University School of Medicine
- 1996- Washington University Cancer Center, Full member
- 1999-2003 Division of Biology and Biomedical Sciences - Graduate Programs Admissions Committee
- 2002-2004 Human Studies Committee – Continuing Review Committee
- 2006- Co-Director, Pathway in Imaging Sciences, Division of Biology and Biomedical Sciences
- 2007- Executive Committee, Division of Radiological Sciences

HONORS AND AWARDS:

- ACS Outstanding Analytical Chemist (UW-Superior) (1984)
- Fellowship, Summer School in Nuclear Chemistry at San Jose State University (1984)
- ACS Outstanding Chemist Award (UW-Superior) (1985)
- Coryell Award for Undergraduate Research in Nuclear Chemistry, Sponsored by the Nuclear Chemistry and Technology Division of the ACS (1986)
- Graduate Student Fellowship, Florida State University (Aug. 1985 - Aug. 1986)
- Travel Contract, Oak Ridge Associated Universities (1988-1990)
- Fellowship, I.I.K.W. Brussels - Research at the Katholieke Universiteit-Leuven, Leuven, Belgium, Jan-April, 1990
- Research Fellowship, Medi-Physics/Society of Nuclear Medicine (1993)
- Steering Committee on IAEA International Conference on “Molecular Nuclear Medicine and Clinical PET”, Bangkok, Thailand, November, 2007
- President’s Award in Education, Society of Nuclear Medicine (2008)

EDITORIAL RESPONSIBILITIES

Associate Editor: Metal-Based Drugs

Editorial Board: Cancer Biotherapy and Radiopharmaceuticals (1999-present)
Bioconjugate Chemistry (2000-present)
Current Cancer Therapy Reviews (2004-present)

Reviewer:	Nuclear Medicine and Biology	Journal of Coordination Chemistry
	Journal of Nuclear Medicine	British Journal of Cancer
	Journal of Medicinal Chemistry	Chemistry and Biology
	Peptides, an International Journal	Molecular Cancer Therapeutics
	International Journal of Cancer	Molecular Imaging
	Radiochimica Acta	Clinical and Experimental Metastasis
	Cancer Research	Clinical Cancer Research
	Molecular Cancer Therapeutics	Journal of Inorganic Biochemistry
	Chemistry and Biology	

PROFESSIONAL SOCIETIES AND MEMBERSHIPS:

The Society of Nuclear Medicine (1991-present)

Radiopharmaceutical Science Council (RPSC) (1993-present)

RPSC - Board of Directors (1997-1999; 2006-2008)

PET Center of Excellence (2005-present)

PET COE – Board of Directors (2005-2007)

Molecular Imaging Center of Excellence (2005-present)

Secretary/Treasurer (2006-2008)

Vice President (2008-present)

Sub-chair - Scientific Program Committee – 1996

Member, Committee on Government Relations (2005)

Member, Committee on Councils (2008-present)

Chair, Committee on Ethics (2005-2008)

The American Chemical Society (ACS) (1986-present)

Division of Nuclear Chemistry and Technology - (1993-present)

Education Committee (1995-1997)

Alternate Councilor (1996-2000)

The American Association of Cancer Research (AACR) (1996-present)

The Society of Molecular Imaging (2001-present)

The Society of Radiopharmaceutical Sciences (2001-present)

Secretary/Treasurer (2003-2005); Board of Directors (2007-present)

Division of Radiopharmacology (2001-2005)

Secretary/Treasurer (2001-2005)

Academy of Molecular Imaging (2004-2006)

NIH/DOE REVIEWS and WORKSHOPS

NCI/NIH Program Project site visitor: University of California-Davis Medical School April 13-15, 1994

NCI/NIH Program Project site visitor: City of Hope Medical Center. October 20-22, 1996

NCI/NIH Program Project Review: City of Hope Medical Center. May 15, 1997

NIH Special Study Section Reviewer: July 14-15, 1997
NIH Special Study Section Reviewer: November 4, 1997
NCI/NIH Program Project Review: Garden State Cancer Center. June 22-24, 1998, January 13, 1999
NIH Special Study Section Reviewer: March 10-11, 1999
NIDDK/NIH Workshop Participant: Imaging Beta Cell Mass in Diabetes; Washington, D.C. April 19-20, 1999
NCI/NIH Workshop Participant: Angiogenesis Imaging Methods for Clinical Trials; Lake Tahoe, NV Feb 26-27, 2000
NCI/NIH Program Project Reviewer: University of Pennsylvania. June 25-27, 2000.
NIGMS/NIH Workshop Invited Speaker: Metals in Medicine, Bethesda, MD; June 28-29, 2000.
DOE Study Section: Cell-targeted Cancer Therapy, Arlington, VA; May 2, 2001
NCI/NIH Program Project site visitor: City of Hope Medical Center. May 20-22, 2001
NCI/NIH Program Project Reviewer: University of Pennsylvania. June 1, 2001
NCI/NIH Program Project Reviewer: University of Pennsylvania. October 31, 2001
NCI/NIH Program Project Reviewer: City of Hope Medical Center. November 16, 2001
NIH Special Study Section Reviewer: November 11-12, 2002; March 10, 2003; March 27, 2003, November 8, 2004, March 14, 2005, September 8-9, 2005, November 9, 2005, July 10, 2006
NCI/NIH Parent Committee D: ad hoc member, August, 2001; December, 2001; April, 2003; August, 2004; April 7, 2005
NCI/NIH Program Project Reviewer: UC-Davis Medical Center. January 22, 2003, October 15, 2003
NCI/NIH Program Project Review: Garden State Cancer Center. June 2, 2004
NIH Special Emphasis Panel: May 2, 2003 (chairperson); July 28, 2004, February 17, 2005
NIH Program Project Cluster Review: February 14-16, 2005
NIH Medical Imaging (MEDI) study section (ad hoc): May 31, 2007; February 14-15, 2008
NIH Medical Imaging (MEDI) study section, charter member: July 2008-present

GUEST LECTURER POSITIONS

Instructor in Radiopharmaceutical Chemistry: Summer School in Nuclear Chemistry, San Jose State University, San Jose, CA: July 24-28, 1995; July 8-12, 1996; July 7-11, 1997; July 6-10, 1998, July 10-13, 2000; July 9-12, 2001; July 7-8, 2003; July 5-6, 2004

Instructor in Radiopharmaceutical Chemistry: Summer School in Nuclear Chemistry, Brookhaven National Laboratory, Upton, NY; July 13-16, 1998

EDUCATIONAL ACTIVITIES

Mentoring

Graduate Student Research Mentor (DBBS): C. Andrew Boswell (defended 2004); Jennifer E. Sprague (defended 2005)

Graduate Student Research Mentor (Chemistry): Ashley L. Fiamengo (in progress); Yunjun Guo (in progress); Kim Nguyen (in progress)

Graduate Student Research Mentor (Technical University – Dresden, Germany): Martin Eiblmaier (2008)

Graduate Student Committees (Chemistry): Buck E. Rogers (1995); Michelle Jones-Wilson (1995); Michael Ortworth (1995); Yvette Fobian (1999); Todd Osiek (2000); Mathew Becker (2003); Monica Shokeen (2006); Efram Mebrahtu (2007); Ajay Kshetry (2008); Alina Handorean (2008); Wei Wang (2008)

Graduate Student Committees (DBBS): Michelle Weber (2005); Amy Caruano (2006); Seth Gammon (2007); Sage Arbor (2008); Sharon Lee (2008)

Undergraduate Research Mentor (WU Biology – Honors Program): Ryan Huffman (2002); Shaun Lan (2003); Nicholas Ramos (2008-present);

Undergraduate Research Mentor (WU Chemistry – Honors Program): Jessica Wilson (2007-present)

External Examiner: Timothy Storr (2005): University of British Columbia Department of Chemistry

Training Programs

PI on two grants to develop curriculum for radiopharmaceutical sciences and molecular imaging

- 1) DOE - Graduate Research in Nuclear Medicine at Washington University (completed, 7-05)
- 2) NIH - Curriculum for Imaging Sciences at Washington University (ongoing)

Team Leader and PI on core of two ongoing grants to lead training efforts in Nanotechnology

- 1) NHLBI - Integrated Nanosystems for Imaging and Therapy (K. Wooley, PI)
- 2) NCI - The Siteman Center of Cancer Nanotechnology Excellence at Washington University (S. Wickline, PI)

Involved in Education and Training for Molecular Imaging Center grant (D. Piwnica-Worms, PI)

Co-Director: Imaging Sciences Pathway – DBBS (2006-present)

Organizing Committee: Imaging Sciences Retreat at Washington University (Chair; April, 2006; April, 2008)

Organizing Committee: CNST Nanotechnology Workshop 2006, Beckman Institute, University of Illinois-Urbana/Champaign, May, 2006

Organizing Committee: Nanotechnology and the Life Sciences Workshop, Washington University, March 30-April 1, 2007

Lead Organizer: Nanotechnology and Imaging Seminar Series (2006-2007; 2007-2008; 2008-2009)

Course master of the following courses

Biology 5074: Radiopharmaceutical Chemistry and Biology: Spring 2002, Spring 2003 and Spring 2004

Biology 5046: Principles and Applications of Biological Imaging: Spring, 2006; Fall, 2007; Fall, 2008

Biology 5047: Contrast Agents for Biological Imaging (Spring, 2007; Spring, 2008; Spring, 2009)

Lecturer for the following courses

Radiochemistry/Radiopharmacy Resident Lectures (1993-present)

Chemistry 555: Special Topics in Organic Chemistry: Nanomedicine; Fall Semester, 2006

INVITED LECTURES (selected):

Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals. Peking University Health Sciences, Beijing, China, May 16, 2005.

Education in Imaging Sciences: The Next Frontier. AAAS Annual Meeting, St. Louis, MO, February 17, 2006.

Coordinating the Chemistry with PET Imaging Applications for Gallium-68 and Copper-64 Radiopharmaceuticals. COST D38 meeting for metal-based imaging agents, Eindhoven, The Netherlands, May 4, 2007.

Multimodality Imaging for Cancer Biologists. NCI Cancer Imaging Camp, Duke University, Durham, NC, June 28, 2007

Copper-64-labeled Biomolecules for PET/CT Imaging of Cancer Metastasis. University of Iowa Department of Radiology, Iowa City, IA, September 13, 2007

A New Generation of Radiometal-based Radiopharmaceuticals for PET Oncological Imaging. International Conference on Clinical PET and Molecular Nuclear Medicine (IPET 2007), Bangkok, Thailand, November 12, 2007.

Non-invasive Imaging of Osteoclasts in Osteolytic Bone Metastases. Vanderbilt University Institute of Imaging Sciences, Nashville, TN, December 7, 2007.

Copper-64-labeled Biomolecules for Molecular Imaging of Cancer Metastasis. Virginia Commonwealth University, Department of Chemistry, Richmond, VA, April 17, 2008

Copper-64-labeled Biomolecules for Molecular Imaging of Cancer Metastasis. Washington State University, Department of Chemistry, Pullman, WA, September 29, 2008

Non-invasive Imaging of Osteoclasts in Osteolytic Bone Metastases, University of Pennsylvania, Department of Radiology, Philadelphia, PA, October 29, 2008.

CURRENT RESEARCH SUPPORT:

Federal Funding:

Principal Investigator, NIH K07 GM072931 (Curriculum for Imaging Sciences at Washington University) 9/30/04-9/29/09, \$83,268 (9/30/07-9/29/08)

Principal Investigator, NIH R01 CA093375 (Radiopharmaceuticals Based on Cross-Bridged Ligands), subcontract to UNH – E.H. Wong, P.I. (1-01-02 to 3-31-12) \$109,392 (4-01-07 to 3-31-08)

Principal Investigator, NIH R01 CA64475 (Labeling of Octreotide with Positron Emitters) 7/1/94-8/31/08, \$188,000 (9/1/06-8/31/08)

Note: Priority score of 130 – grant is scheduled for funding in January, 2009

Team Leader, NIH 1U01 HL080729-01 (Integrated Nanosystems for Imaging and Therapy), K. Wooley, P.I. 5/1/05-4/30/10, \$111,146 (5/1/07-4/30/08)

Core Leader, NIH 1U54CA119342 (The Siteman Center of Cancer Nanotechnology Excellence at Washington University), S. Wickline, P.I. 9/30/05-09/29/10, \$71,568 (9/1/07-8/31/08).

Co-Principal Investigator, NIH T90 DA022871/ R90 DA023416 (21st Century Imaging Sciences: Undergraduate and Graduate Student Training), P. Stahl, P.I. 9/30/06-07/31/010, \$272,825 (9/30/07-7/31/08).

Industrial Funding:

Principal Investigator, Amgen, Inc. (⁶⁴Cu-RGD and microPET/CT as an Imaging Biomarker for Osteoclast Number) \$109,283 (1/1/07-12/31/07).

Principal Investigator, Transmolecular, Inc. (Synthesis, Radiochemistry and Biological Evaluation of ⁶⁴Cu-labeled TM-601 for PET imaging of Tumor) \$147,254 (7/1/07-12/31/08).

COMPLETED RESEARCH SUPPORT (last 3 years):

Principal Investigator, NIH R21 CA098698 (Targeting Matrix Metalloproteinases for Tumor Imaging) 6/1/03-5/31/06, \$125,000 (6/1/04-5/31/06)

Principal Investigator, NIH R43 CA102989 (Copper Complexes for Cancer Imaging and Therapy), subcontract to Macrocyclics, Inc., D. Mudigonda, P.I., (9/30/03-8/31/05), \$40,850

Principal Investigator (development project), NIH P50 CA094056 (Washington University Molecular Imaging Center, D. Piwnicka-Worms, P.I.), 5/31/02-3/31/07, \$20,000 (1/1/05 to 12/31/05)

BIBLIOGRAPHY:

Peer Reviewed Manuscripts:

1. Blaha, SL, Anderson CJ, Choppin GR, Pruett DJ; Evaluation of POCl₃ as a solvent for complexation studies. *Inorganica Chimica Acta* 1989; 156:37-39.
2. Anderson CJ, Deakin MR, Choppin GR, D'Olieslager W, Heerman L, Pruett DJ; Spectroscopy and electrochemistry of U(IV)/U(III) in basic AlCl₃-EMIC. *Inorganic Chemistry* 1991; 30:4013-4016.
3. DiZio JL, Anderson CJ, Davison A, Ehrhardt GJ, Carlson KE, Welch MJ, Katzenellenbogen JA: Technetium and rhenium labeled progestins: synthesis, receptor binding and in vivo distribution of an 11β-substituted progestin labeled with technetium-99 and 99m and rhenium 186. *Journal of Nuclear Medicine* 1992; 33:558-569.
4. Anderson CJ, Connett, JM, Schwarz, SW, Rocque PA, Philpott GW, Guo LW, Zinn KR, Meares CF, Welch MJ: Copper-64 labeled antibodies for PET imaging. *Journal of Nuclear Medicine* 1992; 33:1685-1691.
5. Herrero P, Markham J, Weinheimer CJ, Anderson CJ, Welch MJ, Green MA, Bergmann SR: Quantification of regional myocardial perfusion with generator-produced copper-62-PTSM and positron emission tomography. *Circulation* 1993; 87:173-183.
6. Anderson CJ, Rocque PA, Weinheimer CJ, Welch MJ: Evaluation of copper-labeled bifunctional

- chelate-albumin conjugates for blood pool imaging. *Nuclear Medicine and Biology* 1993; 20:461-467.
7. Anderson CJ, Woods M, Deutsch E, Deutsch K, Sullivan JC: A kinetic study of the reduction of Np(VI) and Pu(VI) in carbonate media by tris[1,2-bis(dimethylphosphino)ethane] complexes of Tc(I) and Re(I). *Radiochimica Acta* 1993; 61:137-139.
 8. Chi DY, O'Neil JP, Anderson CJ, Welch MJ, Katzenellenbogen JA. Homodimeric and heterodimeric bis-aminothiol oxo metal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. *Journal of Medicinal Chemistry*, 1994; 37:928-937.
 9. Schwarz SW, Connett JM, Anderson CJ, Rocque PA, Philpott GW, Guo LW, Welch MJ. Evaluation of a direct method for technetium labeling intact and F(ab')₂ 1A3, an anticolorectal monoclonal antibody. *Nuclear Medicine and Biology*, 1994; 21:619-626.
 10. O'Neil JP, Carlson KE, Anderson CJ, Welch MJ, Katzenellenbogen JA. Progesterin radiopharmaceuticals labeled with technetium and rhenium: synthesis, binding affinity and *in vivo* distribution of a new N₂S₂-metal conjugate. *Bioconjugate Chemistry*, 1994; 5:182-193.
 11. Edwards WB, Fields CG, Anderson CJ, Pajeau TS, Welch MJ, Fields GB. Generally applicable, convenient solid phase synthesis and *in vitro* receptor binding of octreotide analogs. *Journal of Medicinal Chemistry*, 1994; 37:3749-3757.
 12. Katti KK, Singh PR, Volkert WA, Anderson CJ, Welch MJ, Hoffman T, Katti KV, Ketring AR, Wang M. Synthesis and characterization of a neutral and lipophilic Ph₃PN^{99m}TcO₃ complex. *International Journal of Applied Radiation and Isotopes*, 1995; 46:53-58.
 13. Anderson CJ, John CS, Li YJ, Hancock RJ, McCarthy TJ, Martell AE, Welch MJ. N,N'-ethylene-di-L-cysteine (EC) complexes of Ga(III) and In(III): molecular modeling, thermodynamic stability and *in vivo* studies. *Nuclear Medicine and Biology*, 1995; 22:165-173.
 14. Anderson CJ, Schwarz SW, Connett JM, Cutler PD, Guo LW, Germain CJ, Philpott GW, Zinn KR, Greiner DP, Meares CF, Welch MJ. Preparation, biodistribution, and dosimetry of copper-64-labeled anti-colorectal carcinoma antibody (MAb) fragments 1A3-F(ab')₂. *Journal of Nuclear Medicine* 1995; 36:850-858.
 15. Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR, Meares CF, Cutler PD, Welch MJ, Siegel BA. RadioimmunoPET: Detection of colorectal carcinoma by positron emission tomography with a ⁶⁴Cu-labeled monoclonal antibody. *Journal of Nuclear Medicine* 1995; 36:1818-1824.
 16. Jones-Wilson TM, Motekaitis RJ, Sun Y, Anderson CJ, Martell AE, Welch MJ. New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium (III) and indium (III). *Nuclear Medicine and Biology*, 1995; 22:859-868.
 17. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. *In vitro* and *in vivo* evaluation of copper-64-labeled octreotide conjugates. *Journal of Nuclear Medicine*, 1995; 36:2315-2325.
 18. Cutler PD, Schwarz SW, Anderson CJ, Connett JM, Welch MJ, Philpott GW, Siegel BA. Dosimetry of ⁶⁴Cu-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. *Journal of Nuclear Medicine*, 1995; 36:2363-2371.
 19. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, Welch MJ. Identification of metabolites of In-111-DTPA-monoclonal antibodies and antibody fragments *in vivo*. *Cancer Research* 1995; 55(23 suppl 5):S5714-S5720.
 20. Li Y, Martell AE, Hancock RD, Reibenspies JH, Anderson CJ, Welch MJ. N,N'-ethylenedi-L-cysteine (EC) and its metal complexes: synthesis, characterization, crystal structures and equilibrium constants. *Inorganic Chemistry*, 1996; 35:404-414.

21. Sun Y, Anderson CJ, Pajeau TS, Reichert DE, Hancock RD, Motekaitis RJ, Martell AE, Welch MJ. Indium(III) and gallium(III) complexes of bis(aminoethanethiol) ligands with different denticities: stabilities, molecular modeling and *in vivo* behavior. *Journal of Medicinal Chemistry*, 1996; 39:458-470.
22. Connett JM, Anderson CJ, Guo LW, Schwarz SW, Zinn KR, Rogers BE, Siegel BA, Philpott GW, Welch MJ. Radioimmunotherapy with a Cu-64 labeled monoclonal antibody: a comparison with Cu-67. *Proceedings of the National Academy of Sciences, U.S.A.*, 1996; 93:6814-6818.
23. Rogers BE, Anderson CJ, Connett JM, Guo LW, Edwards WB, Sherman ELC, Zinn KR, Welch MJ. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. *Bioconjugate Chemistry*, 1996; 7:511-522.
24. Herrero P, Hartman JJ, Green MA, Anderson CJ, Welch MJ, Markham J, Bergmann SR. Assessment of regional myocardial perfusion with generator-produced ⁶²Cu-PTSM and PET in human subjects. *Journal of Nuclear Medicine*, 1996; 37:1294-1300.
25. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-DTPA-Octreotide is delivered to pancreatic, tumor cell, renal and hepatocyte lysosomes. *Cancer Research*, 1997; 57:659-671.
26. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margenau WH, Cutler CS, Anderson CJ, Welch MJ. The efficient production of high specific activity ⁶⁴Cu using a biomedical cyclotron. *Nuclear Medicine and Biology*, 1997; 24:35-43.
27. Downer JB, McCarthy TJ, Edwards WB, Anderson CJ, Welch MJ. Reactivity of *p*-[¹⁸F]fluorophenacyl bromide for radiolabeling of proteins and peptides. *Applied Radiation and Isotopes* 1997; 48:907-916.
28. Bass, LA, Lanahan, MV, Duncan JR, Erion JL, Srinivasan A, Schmidt MA, Anderson CJ. Identification of the soluble *in vivo* metabolites of Indium-111-diethylenetriaminepentaacetic acid-D-Phe¹-octreotide. *Bioconjugate Chemistry*, 1998; 9:192-200.
29. Jones-Wilson TM, Deal KA, Anderson CJ, McCarthy DW, Kovacs Z, Motekaitis RJ, Sherry AD, Martell AE, Welch MJ. The *in vivo* behavior of copper-64-labeled azamacrocyclic complexes. *Nuclear Medicine and Biology*, 1998; 25:523-530.
30. Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW. Radiotherapy, toxicity and dosimetry of copper-64-labeled-TETA-octreotide in tumor-bearing rats. *Journal of Nuclear Medicine*, 1998; 39:1944-1951.
31. Spradau TW, Edwards WB, Anderson CJ, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of Tc-99m-cyclopentadienylnitric carbonyl technetium-labeled octreotide. *Nuclear Medicine and Biology*, 1999; 26:1-7.
32. Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, Sharp T, Yonekura Y, Welch MJ. Comparative studies of Cu-64 ATSM and C-11-acetate in an acute myocardial infarction model: *ex vivo* imaging of hypoxia in rats. *Nuclear Medicine and Biology*, 1999; 26:117-121.
33. Lewis JS, Lewis, MR, Srinivasan A, Schmidt MA, Anderson CJ. Structure-activity studies of Cu-64-labeled somatostatin analogs for diagnostic imaging and targeted radiotherapy. *Technetium, Rhenium and Other Radiometals in Chemistry and Nuclear Medicine*, 5th Ed., M Nicolini and U Mazzi (eds), Servizi Grafici Editoriali, Padova, 1999, pp. 53-58.
34. Welch MJ, Reichert DE, Anderson CJ, Martell AE. Chemistry of gallium, indium and copper in the design of new radiopharmaceuticals. *Technetium, Rhenium and Other Radiometals in Chemistry and Nuclear Medicine*, 5th Ed., M Nicolini and U Mazzi (eds), Servizi Grafici Editoriali, Padova, 1999, pp. 43-52.
35. Edwards WB, Anderson CJ, Fields GB, Welch MJ. Evaluation of collagen-based peptides as imaging agents for $\alpha\beta 1$ integrin. *Technetium, Rhenium and Other Radiometals in Chemistry*

- and Nuclear Medicine, 5th Ed., M Nicolini and U Mazzi (eds), Servizi Grafici Editoriali, Padova, 1999, pp. 527-532.
36. Lewis JS, Srinivasan, A, Schmidt, MA, Anderson CJ. In vitro and in vivo evaluation of ⁶⁴Cu-TETA-Tyr³-octreotate. A new somatostatin analog with improved target tissue uptake. Nuclear Medicine and Biology, 1999; 26: 267-273.
 37. Cutler CS, Giron MC, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, Quarless DA, Koch SA, Welch MJ. Evaluation of gallium-68 tris(2-Mercaptobenzyl)Amine: a complex with brain and myocardial uptake. Nuclear Medicine and Biology, 1999; 26:305-316.
 38. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four ⁶⁴Cu-labeled somatostatin analogs *in vitro* and in a tumor-bearing rat model: evaluation of new derivatives for PET imaging and targeted radiotherapy. Journal of Medicinal Chemistry, 1999; 42:1341-1347.
 39. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS, Anderson CJ, Welch MJ. High purity production and potential applications of copper-60 and copper-61. Nuclear Medicine and Biology, 1999; 26:351-358.
 40. Anderson CJ, Choppin GR, Pruett DJ, Costa D, Smith W. Electrochemistry and spectroscopy of UO₂²⁺ in acidic AlCl₃-EMIC. Radiochimica Acta, 1999; 84:31-36.
 41. Connett JM, Buettner TL, Anderson CJ. Maximum tolerated dose and large tumor radioimmunotherapy studies of ⁶⁴Cu-labeled Mab 1A3 in a colon cancer model. Clinical Cancer Research, 1999; 5:3207s-3212s.
 42. Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SVS, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT. Targeting Strategies for Cancer Radiotherapy. Clinical Cancer Research, 1999; 5:3048s-3055s.
 43. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ. Radiotherapy and dosimetry of ⁶⁴Cu-TETA-Tyr³-octreotate in a somatostatin receptor-positive tumor-bearing rat model. Clinical Cancer Research, 1999; 5:3608-3616.
 44. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjugate Chemistry, 2000; 11:527-532.
 45. Cutler CS, Wuest M, Anderson CJ, Reichert DE, Sun Y, Martell AE, Welch MJ. Labeling and *In Vivo* Evaluation of Novel Copper(II) Dioxotetraazamacrocyclic Complexes. Nuclear Medicine and Biology, 2000; 27:375-380.
 46. Lewis JS, Laforest R, Lewis MR, Anderson CJ. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy and Radiopharmaceuticals, 2000; 15:593-604.
 47. Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW. Copper-64-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. Journal of Nuclear Medicine, 2001; 42:213-221.
 48. Duncan JR, Anderson CJ, Arano Y. Nuclear translocation of somatostatin analogs, Letter to the Editor, Journal of Nuclear Medicine, 2001; 42:529-530.
 49. Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of ¹⁷⁷Lu-DOTA-Y3-octreotate in a rat model. International Journal of Cancer, 2001; 94:873-877.
 50. Edwards WB, Anderson CJ, Fields GB, Welch MJ. Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents. Bioconjugate Chemistry, 2001; 12:1057-1065.
 51. Lewis MR, Boswell CA, Laforest R, Buettner TL, Ye D, Connett JM, Anderson CJ. Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of ⁶⁴Cu-TETA-1A3 with ⁶⁴Cu-BAT-2IT-1A3. Cancer Biotherapy and Radiopharmaceuticals,

- 2001; 16: 483-494.
52. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, Motekaitis R, Martell AE, Welch MJ, Anderson CJ. Radiolabeling and *in vivo* behavior of copper-64-labeled cross-bridged ligands. *Journal of Medicinal Chemistry*, 2002; 45:469-477.
 53. Li WP, Lewis JS, Kim J, Bugaj JE, Erion JL, Johnson ML, Anderson CJ. DOTA-D-Tyr¹-Octreotate: a somatostatin analog for labeling with metal and halogen radionuclides for cancer imaging and therapy. *Bioconjugate Chemistry*, 2002; 13:721-728.
 54. Sun X, Wuest M, Kovacs Z, Sherry AD, Motekaitis R, Wang Z, Martell AE, Welch MJ, Anderson CJ. *In Vivo* Behavior of Copper-64-Labeled Methanephosphonate Tetraazamacrocyclic Ligands. *Journal of Biological Inorganic Chemistry*, 2003; 8:217-225.
 55. Ye Y, Li WP, Anderson CJ, Kao J, Nikiforovich G, Achilefu S. Synthesis and characterization of a near-infrared optical scaffold. *Journal of the American Chemical Society*, 2003; 125:7766-7767.
 56. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ. *In vivo* Evaluation of Pre-targeted Copper-64 for Tumor Imaging and Therapy. *Journal of Nuclear Medicine*, 2003; 44:1284-1292.
 57. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogs: implications for cancer therapy. *Cancer Research*, 2003; 63:6864-6869.
 58. Boswell CA, Sun X, Niu W, Wong EH, Weisman GR, Rheingold AL, Anderson CJ. Comparative *in vivo* Stability of Copper-64-Labeled Cross-bridged and Conventional Tetraazamacrocyclic Complexes. *Journal of Medicinal Chemistry*, 2004; 47:1465-1474.
 59. Niu W, Wong EH, Weisman GR, Peng Y, Anderson CJ, Zhakarov LN, Golen JA, Rheingold AL. Structure and dynamic studies of the zinc and gallium complexes of dicarboxylate pendant-armed cross-bridged cyclen. *European Journal of Inorganic Chemistry*, 2004: 3310-3315.
 60. Bryan JN, Lewis MR, Henry CJ, Owen NK, Zhang J, Mohsin H, Jia F, Sivaguru G, and Anderson CJ. Development of a Two-Antibody Model for Evaluation of Copper-64 Radioimmunotherapy. *Veterinary and Comparative Oncology*, 2004; 2:82-90.
 61. Sun X, Kim J, Martell AE, Welch MJ, Anderson CJ. *In Vivo* Evaluation of Copper-64-Labeled Monoxo-Tetraazamacrocyclic Ligands. *Nuclear Medicine and Biology*, 2004; 8:1049-1057.
 62. Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ. Preparation and Biological Evaluation of Copper-64-labeled Tyr³-octreotate using a Cross-Bridged Macrocyclic Chelator. *Clinical Cancer Research*, 2004; 10:8674-8682.
 63. Boswell CA, McQuade P, Weisman GR, Wong EH, Anderson CJ. Optimization of Labeling and Metabolite Analysis of Copper-64-Labeled Azamacrocyclic Chelators by Radio-LC-MS. *Nuclear Medicine and Biology*, 2005; 32:29-38.
 64. Yoo J, Reichert DE, Kim JY, Anderson CJ, Welch MJ. A potential Dubin-Johnson syndrome imaging agent: Synthesis, biodistribution, and microPET imaging. *Molecular Imaging*, 2005; 4:18-29.
 65. Bryan JN, Jia F, Mohsin H, Sivaguru G, Miller WH, Anderson CJ, Henry CJ, Lewis MR. Comparative uptakes and biodistributions of internalizing versus non-internalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. *Nuclear Medicine and Biology*, 2005; 32:851-858.
 66. Woodin KS, Heroux KJ, Boswell CA, Wong EH, Weisman GR, Niu W, Tomellini SA, Anderson CJ, Zakharov LN, Rheingold AL. Kinetic inertness and electrochemical behavior of Cu(II) tetraazamacrocyclic complexes: possible implications for *in vivo* stability. *European Journal of Inorganic Chemistry*, 2005; 23:4829-4833.

67. Shen X, Boswell CA, Wong EH, Weisman GR, Anderson CJ, Tomellini SA. Investigation of Cu-Azamacrocyclic Complexes by HPLC. *Biomedical Chromatography*, 2006; 20:37-47.
68. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. *Nuclear Medicine and Biology*, 2006; 33:227-237.
69. Edwards WB, Liang K, Xu B, Anderson CJ, Achilefu S. Synthesis and radiolabeling of a somatostatin analog for multimodal imaging. *Proceedings of SPIE-The International Society for Optical Engineering* (2006), 6097(Optical Molecular Probes for Biomedical Applications).
70. Fiamengo AL, Capretto DA, Sprague JE, Peng Y, Weisman GR, Wong EH, Anderson CJ. *In vivo* evaluation of ⁶⁴Cu-labeled cross-bridged tetraazamacrocyclic complexes with amide and/or carboxylate functional groups, Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, 7th Ed., U Mazzi (ed), Servizi Grafici Editoriali, Padova, 2006, pp. 235-236.
71. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Development of Chelators for Copper-64 Radiopharmaceuticals: Optimizing for *in vivo* Stability, Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine, 7th Ed., U Mazzi (ed), Servizi Grafici Editoriali, Padova, 2006, pp. 215-218.
72. Wadas TJ, Anderson CJ. Labeling of TETA-and CB-TE2A-conjugated peptides with copper-64. *Nature Protocols*, 2006; 1:3062-3068.
73. Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, Teitelbaum SL, Anderson CJ. Non-invasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a ⁶⁴Cu-labeled RGD Peptide. *Journal of Nuclear Medicine*, 2007; 48: 311-318.
74. Parry JJ, Eiblmaier M, Andrews R, Meyer LA, Higashikubo R, Anderson CJ, Rogers BE. Characterization of Somatostatin Receptor Subtype 2 Expression in Stably Transfected A-427 Human Cancer Cells. *Molecular Imaging*, 2007; 6:56-67.
75. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR, Wong EH, Golen JA, Rheingold AL, Anderson CJ. Synthesis, Characterization and *in vivo* Studies of Cu(II)-64-labeled Cross-bridged Tetraazamacrocyclic-amide Complexes as Models of Peptide Conjugate Imaging Agents. *Journal of Medicinal Chemistry*, 2007; 50:2527-2535.
76. Heroux KJ, Woodin KS, Tranchemontagne DJ, Widger PCB, Southwick EA, Wong EH, Weisman GR, Tomellini SA, Wadas TJ, Anderson CJ, Kassel S, Golen JA, Rheingold AL. The Long and Short of It: The Influence of N-Carboxyethyl versus N-Carboxymethyl Pendant Arms on in vitro and in vivo Behavior of Copper Complexes of Cross-bridged Tetraamine Macrocycles. *Dalton Transactions*, 2007; 2150-2162.
77. Eiblmaier M, Andrews R, Laforest R, Rogers BE, Anderson CJ. Nuclear Uptake and Dosimetry of ⁶⁴Cu-labeled Chelator-Somatostatin Conjugates in a SSTR2-transfected Human Tumor Cell Line. *Journal of Nuclear Medicine*, 2007; 1390-1396.
78. Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, Anderson CJ, Achilefu S. The agonist-antagonist dilemma in molecular imaging: Evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. *Bioconjugate Chemistry*, 2008; 19:192-200
79. Eiblmaier M, Meyer LA, Anderson CJ. The Role of p53 in the Trafficking of Copper-64 to Tumor Cell Nuclei. *Cancer Biology and Therapy*, 2008; 7:63-69.
80. Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor binding, biodistribution and metabolism studies of ⁶⁴Cu-DOTA-cetuximab, a PET imaging agent for epidermal growth factor receptor positive tumors. *Cancer Biotherapy and Radiopharmaceuticals*, 2008; 23:158-171.
81. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR expression with receptor binding properties and internalization of ⁶⁴Cu-DOTA-C225 in

- five cervical cancer cell lines. *Journal of Nuclear Medicine*, 2008; 49:1472-1479.
82. Wadas TJ, Eiblmaier M, Zheleznyak A, Sherman CD, Ferdani R, Liang K, Achilefu S, Anderson CJ. Preparation and biological evaluation of ^{64}Cu -CB-TE2A-sst₂-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor positive tumors. *Journal of Nuclear Medicine*, 2008; 49:1819-1827.
 83. Papini G, Alidori S, Lewis JS, Reichert DE, Pellei M, Gioia Lobbia G, Biddlecomb GB, Anderson CJ, Santini C. Synthesis and Characterization of the Copper(II) Complexes of New N₂S₂-donor Macrocyclic Ligands: Synthesis and In Vivo Evaluation of the ^{64}Cu Complexes. *Dalton Transactions*, 2009; 177-184.
 84. Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ, Fréchet JMJ. Biodegradable dendritic positron emitting nanoprobes for the non invasive imaging of angiogenesis. *Proceedings of the National Academy of Sciences USA*, 2009; 106:685-690.
 85. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. ^{64}Cu -Labeled CB-TE2A and Diamsar Conjugated RGD Peptide Analogs for Targeting Angiogenesis: Comparison of their Biological Activity. *Nuclear Medicine and Biology*, in press.
 86. DeNardo SJ, Liu R, Albrecht H, Natarajan A, Sutcliffe JL, Anderson CJ, Peng L, Yuan A, Ferdani R, Cherry SR, Lam KS. ^{111}In -LLP2A-DOTA PEG Targeting $\alpha_4\beta_1$ Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies. *Journal of Nuclear Medicine*, in press.
 87. Hausner SH, Kukis, DL, Gagnon KJ, Stanecki CE, Ferdani R, Marshall JF, Anderson CJ, Sutcliffe JL. Evaluation of [^{64}Cu]Cu-DOTA and [^{64}Cu]Cu-CB-TE2A chelators for targeted PET imaging with an $\alpha_v\beta_6$ -specific peptide. *Molecular Imaging*, in press.

Invited Publications:

1. Schwarz SW, Anderson CJ, Welch MJ: Radiochemistry and radiopharmacology. In *Nuclear Medicine Technology and Techniques*, 3rd Ed., DR Bernier, P Christian, LD Wells (eds), Mosby Year Book, St. Louis 1994, pp.142-161.
2. Anderson CJ, Welch MJ: Gallium. In *Handbook on Metals in Clinical and Analytical Chemistry*, H.G. Seiler, A. Sigel, H. Sigel (eds), Marcel Dekker, Inc., New York 1994, pp. 371-380.
3. Anderson CJ, Schwarz SW, Welch MJ: Indium. In *Handbook on Metals in Clinical and Analytical Chemistry*, H.G. Seiler, A. Sigel, H. Sigel (eds), Marcel Dekker, Inc., New York 1994, pp. 401-408.
4. Anderson CJ, Bergmann SR. In search of the perfect PET flow tracer [editorial]. *Journal of Nuclear Medicine*, 1994; 35:1122-1124.
5. Schwarz SW, Anderson CJ, Downer JB. Radiochemistry and Radiopharmacology. In *Nuclear Medicine Technology and Techniques*, 4th Ed., DR Bernier, P Christian, JK Langan (eds), Mosby Year Book, St. Louis, 1997.
6. Reichert DE, Anderson CJ, Welch MJ. Metal radionuclides for imaging and therapy. *Chemistry and Industry*, September 21, 1998 p. 730-733.
7. Reichert DE, Lewis JS, Anderson CJ. Metal Complexes as Diagnostic Tools. *Coordination Chemistry Reviews* 1999; 184:3-66.
8. Cutler CS, Lewis JS, Anderson CJ. Utilization of Metabolic, Transport and Receptor-Mediated Processes to Deliver Agents for Cancer Diagnosis. *Advanced Drug Delivery Reviews* 1999; 37:189-212.
9. Anderson CJ, Welch MJ. Radiometal-labeled agents (non-technetium) for diagnostic imaging.

- Chemical Reviews, 1999; 99:2219-2234.
10. Anderson CJ, Lewis JS. Radiopharmaceuticals for targeted radiotherapy of cancer. *Expert Opinion in Therapeutic Patents*, 2000; 10:1057-1069.
 11. Blankenberg FG, Eckelman WC, Strauss W, Welch MJ, Alavi A, Anderson CJ, Bacharach S, Blasberg RG, Graham MM, Weber W. Role of radionuclide imaging in trials of antiangiogenic therapy. *Academic Radiology*, 2000; 7:851-867.
 12. Anderson CJ. Metabolism of radiometal-labeled proteins and peptides: what are the real radiopharmaceuticals *in vivo*? [editorial] *Cancer Biotherapy and Radiopharmaceuticals*, 2001; 16:451-455.
 13. Anderson CJ, Green MA, Fujibayashi Y. Chemistry of Copper Radionuclides and Radiopharmaceutical Products. In *Handbook of Radiopharmaceuticals: Radiochemistry and Applications*, MJ Welch and C. Redvanly (eds). John Wiley & Sons, Ltd., 2003, pp 401-422.
 14. Piwnica-Worms, D., Luker, G.D., Anderson, C.J., Wahl, R.L. Molecular Imaging in Oncology. In: *Molecular Nuclear Medicine: The Challenge from the Human Genome*. Feinendegen, L.E., Shreeve, W.W., Eckelman, W.C., Bahk, Y-W., Wagner, Jr., H.N. (editors), Springer-Verlag, Germany, 2003, pp 633-652.
 15. Schwarz SW, Anderson CJ. Radiochemistry and Radiopharmacology. In *Nuclear Medicine Technology and Techniques*, 5th Ed., DR Bernier, P Christian, JK Langan (eds), Mosby Year Book, St. Louis, 2003, pp 157-183.
 16. Li WP, Anderson CJ. Imaging matrix metalloproteinase expression in tumors. *Quarterly Journal of Nuclear Medicine*, 2003, 47:201-208.
 17. Madden EF, Anderson CJ, Goering PL. Indium. In *Elements and Their Compounds in the Environment*, 2nd Ed., M. Anke, M. Ihnat and M. Stoepler (Eds), WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2004, pp. 801-809.
 18. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. *Methods in Enzymology*, 2004; 386:237-261.
 19. Li WP, Meyer LA, Anderson CJ. Radiopharmaceuticals for PET imaging of somatostatin receptor positive tumors. *Topics in Current Chemistry*, 2005; 252:179-192.
 20. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. *Current Pharmaceutical Design*, 2007; 13:3-16.
 21. Lewis JS, Anderson CJ. Radiometal-labeled somatostatin analogues for applications in cancer imaging and therapy. In *Methods in Molecular Biology (Peptide Characterization and Application Protocols)*, G.B. Fields (Ed), Volume 386. Humana Press (Totowa, NJ), 2007 pp. 227-240.
 22. Anderson CJ. Imaging matrix metalloproteinase expression: applications for cardiovascular imaging. In *Textbook of Cardiovascular Imaging*, R.J. Gropler, D.K. Glover, A.J. Sinusas and H. Taegtmeyer (Eds), Informa Healthcare USA Inc., 2007 pp 303-308.
 23. Schwarz SW, Anderson CJ. Radiochemistry and Radiopharmacology. In *Nuclear Medicine Technology and Techniques*, 6th Ed., DR Bernier, P Christian, JK Langan (eds), Mosby Year Book, St. Louis, 2007.
 24. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, 2008; 52:185-192.
 25. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors. *Current Pharmaceutical Design*, 2008; 2983-2998.
 26. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper Radiopharmaceuticals and positron emission tomography (PET). *Accounts of Chemical Research*, under review.

27. Holland JP, Ferdani R, Anderson CJ, Lewis, JS. Copper-64 radiopharmaceuticals for oncologic imaging. PET Clinics, under review.

Selected Abstracts

1. Wadas TJ, Sprague JE, Deng H, Ye Y, Achilefu S, Weilbaecher K, Anderson CJ. Monitoring the effects of bisphosphonate treatment in a mouse model of osteolytic bone disease using microPET and microCT. AACR Pathobiology Conference, July, 2006.
2. Wadas TJ, Sprague JE, Deng H, Ye Y, Achilefu S, Weilbaecher K, Anderson CJ. Monitoring the effects of bisphosphonate treatment in a mouse model of osteolytic bone disease using microPET and microCT. European Journal of Nuclear Medicine and Molecular Imaging 2006; 33 (suppl 2):S227.
3. Meyer LA, Eiblmaier M, Anderson CJ. Potential role of tumor suppressor protein p53 in the trafficking of copper to the nuclei of tumor cells. J. Lab. Compd. Radiopharm. 2007; 50 (suppl 1): S16.
4. Capretto DA, Wadas TJ, Fiamengo AL, Sherman CD, Wong EH, Weisman GR, Anderson CJ. In vivo evaluation of copper-64-labeled cross-bridged tetraazamacrocyclic complexes with amide and/or carboxylate functional groups. J. Lab. Compd. Radiopharm. 2007; 50 (suppl 1): S252.
5. Eiblmaier M, Laforest R, Parry JJ, Andrews R, Rogers BE, Anderson CJ. Internalization, efflux and dosimetry of two ⁶⁴Cu-labeled somatostatin analogs in a human SSTR2-transfected cell line. J. Lab. Compd. Radiopharm. 2007; 50 (suppl 1): S389.
6. Wei L, Ye Y, Wadas TJ, Lewis JS, Welch MJ, Anderson CJ. ⁶⁴Cu-labeled CB-TE2A and Sar conjugated RGD peptide analogs for targeting angiogenesis: Comparison of their biological activity. Journal of Nuclear Medicine 2007; 48:69P.
7. Anderson CJ, Wadas TJ, Sprague JE, Deng H, Weilbaecher KN. MicroPET imaging of alpha v beta 3 expression on osteoclasts related to osteolytic bone metastases. Oral Presentation, American Chemical Society Meeting, Boston, MA, August, 2007.
8. Fiamengo AL, Shokeen M, Li Z, Sun G, Xu Z, Pressly E, Hawker C, Wooley KL, Anderson CJ. Binding Affinity Determination of RGD-Functionalized Nanoparticles to $\alpha_v\beta_3$ and $\alpha_v\beta_5$ Integrins. Oral Presentation, American Chemical Society Meeting, Boston, MA, August, 2007.
9. Shokeen M, Fiamengo AL, Rossin R, Pressly ED, Fukakawa K, Almutairi A, Welch MJ, Hawker CJ, Fréchet JMJ, Anderson CJ. Developing Optimized High Throughput Assays for Screening $\alpha_v\beta_3$ -Targeted Nanoparticles for Diagnosis and Therapy. Oral Presentation, Joint Molecular Imaging Conference, Providence, RI, September, 2007.
10. Anderson CJ, Welch MJ. Graduate training in imaging sciences at Washington University. Oral Presentation, American Nuclear Society Annual Meeting, Anaheim, CA June 11, 2008
11. Fiamengo AL, Ye Y, Achilefu S, Anderson CJ. Binding affinity and cellular internalization of $\alpha_v\beta_3$ targeting ligands for molecular imaging of cancer and cardiovascular disease. Oral Presentation, American Chemical Society Annual Fall Meeting, Philadelphia, PA August 19, 2008.
12. Anderson CJ, Sobotka, LG. Nuclear and radiochemistry at Washington University in St. Louis. MARC VIII conference, Kona, HI, April 5-10, 2009.